The estimated Net Worth of Daniel Guthrie is at least $2.1 Milión dollars as of 12 March 2020. Mr. Guthrie owns over 5,000 units of Neuronetics Inc stock worth over $108,673 and over the last 6 years he sold STIM stock worth over $53,543. In addition, he makes $1,937,180 as Chief Commercial Officer at Neuronetics Inc.
Daniel has made over 4 trades of the Neuronetics Inc stock since 2018, according to the Form 4 filled with the SEC. Most recently he bought 5,000 units of STIM stock worth $11,800 on 12 March 2020.
The largest trade he's ever made was buying 5,000 units of Neuronetics Inc stock on 12 March 2020 worth over $11,800. On average, Daniel trades about 1,409 units every 69 days since 2018. As of 12 March 2020 he still owns at least 146,855 units of Neuronetics Inc stock.
You can see the complete history of Mr. Guthrie stock trades at the bottom of the page.
Daniel Guthrie serves as Chief Commercial Officer of the Company. Prior to joining our company, Mr. Guthrie was Vice President of Commercialization at JADAK, a business unit of Novanta Inc., from January 2017 to April 2018. Prior to JADAK, Mr. Guthrie was a General Manager at Zimmer Biomet Holdings Inc. from August 2011 to December 2016, where, among other roles, he lead the Asia Pacific business for the company’s dental implant division and regenerative therapies group. Mr. Guthrie was a Director of Franchise Marketing for BioSurgery from May 2008 to August 2011 and a Director of Global Product Marketing from May 2005 to July 2008 at Medtronic PLC (formerly Covidien Ltd.), where he worked in the surgical solutions and patient care and safety business units. Prior to Medtronic, Mr. Guthrie was Regional Marketing Manager, Asia at Fleet Laboratories from May 2000 to December 2004. Mr. Guthrie earned his bachelor’s degree in finance and marketing from American University and his MBA from Southern Illinois University at Carbondale.
As the Chief Commercial Officer of Neuronetics Inc, the total compensation of Daniel Guthrie at Neuronetics Inc is $1,937,180. There are no executives at Neuronetics Inc getting paid more.
Daniel Guthrie is 43, he's been the Chief Commercial Officer of Neuronetics Inc since 2018. There are 13 older and no younger executives at Neuronetics Inc. The oldest executive at Neuronetics Inc is Wilfred Jaeger, 64, who is the Independent Director.
Daniel's mailing address filed with the SEC is C/O NEURONETICS, INC., 3222 PHOENIXVILLE PIKE, MALVERN, PA, 19355.
Over the last 6 years, insiders at Neuronetics Inc have traded over $9,582,393 worth of Neuronetics Inc stock and bought 1,499,267 units worth $4,708,316 . The most active insiders traders include Capital Llc Cannell, Ronald Hunt a Glenn P Muir. On average, Neuronetics Inc executives and independent directors trade stock every 20 days with the average trade being worth of $21,199. The most recent stock trade was executed by Glenn P Muir on 5 September 2024, trading 25,000 units of STIM stock currently worth $20,000.
with neurostar advanced therapy, neuronetics, inc., is the market leader in transcranial magnetic stimulation technology for the treatment of major depressive disorder. based in malvern, pa, we are a privately held medical device company focused on developing non-invasive therapies for psychiatric and neurological disorders using mri-strength magnetic field pulses. we are the first company to have a non-systemic and non-invasive depression treatment cleared by the fda for patients who have not benefited from prior antidepressant medication. neuronetics markets neurostar advanced therapy throughout the united states and select markets around the world. if you have questions or comments about neurostar, please e-mail us at customersupport@neuronetics.com. for u.s. phone support, please call us at (877) 600-7555, for international customers, our number is +1 (610) 640-4207.
Neuronetics Inc executives and other stock owners filed with the SEC include: